Avalyn Pharma Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Avalyn Pharma Inc. (AVLN) reported Adjustments to Additional Paid in Capital, Warrant Issued of $184.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-12
- Avalyn Pharma Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-06-30 was $0.00.
- Avalyn Pharma Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-03-31 was $184.00K.
- Avalyn Pharma Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-06-30 was $0.00.
- Avalyn Pharma Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-03-31 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $184.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $184.00K 10-Q · filed 2026-08-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |